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As the ﬁrst wave of biopharmaceuticals is set to expire, biosimilars or follow-on protein products (FOPPs) have emerged. The
regulatory foundation for these products is more advanced and better codiﬁed in Europe than in the US. Recent approval of
biosimilar Somatropin (growth hormone) in Europe and the US prompted this paper. The scientiﬁc viability of biosimilar growth
hormone is reviewed. Eﬃcacy and safety data (growth rates, IGF-1 generation) for up to 7 years for pediatric indications measure
up favorably to previously approved growth hormones as reference comparators. While the approval in the US is currently only
for treatment of growth hormone deﬁciency (GHD) in children and adults, the commercial use of approved biosimilar growth
hormones will allow in the future for in-depth estimation of their eﬃcacy and safety in non-GH deﬁcient states as well.
Copyright © 2009 Paul Saenger. This is an open access article distributed under the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Recombinant protein drugs approved by the FDA over the
past 25 years have become a cornerstone of medical and
especially endocrine practice [1]( Table 1).
As the ﬁrst wave of biopharmaceuticals has expired or is
about to approach expiry, the opportunity for the develop-
ment of subsequent biosimilar or follow-on protein product
(FOPP) versions of these products has emerged. However,
second entry biopharmaceuticals diﬀer signiﬁcantly from
traditional chemical generics (Table 2).
In the standard pharmaceutical sector, competition from
cost-eﬀectivegenericmedicinesisencouragedformanyyears
now to stimulate innovation and to free up health care
budget resources [1].
Biosimilars, unlike conventional generic drugs, require
more quality data and therefore must demonstrate full com-
parability (including immunogenicity data), to the reference
product. This of course begs the question: what is the incen-
tive to develop a biosimilar? Unlike with traditional generic
products, there is the potential in Europe to extrapolate to all
indications of the reference product (in this case Humatrope
or Genotropin), which may go part of the way answering this
question [2].
One way this is achieved is by providing an abridged
registration procedure which allows an applicant to apply
for marketing authorization of a patent-free medicine to
replace full clinical trials with noninferiority bioequivalence
studies. The manufacturer must prove the quality of the
generic product and, since the safety and eﬃcacy of the
active substance are already well known, the generic has to
demonstrate its therapeutic equivalence with the original
product through what are called bioequivalence studies [3].
2. HistoricalPerspectives
Due to the complexity of biotechnology-derived products
and the sensitive manufacturing process involved, the stan-
dard generic approach is not appropriate for biopharmaceu-
ticals,andaspeciﬁclegalpathwayfortheregistrationofthese
products was needed. In the EU, the current provisions of
European Medical Evaluation Agency (EMEA) for approval
of what have come to be called “similar biological medicinal
products or biosimilars” have been in force since October
2005 (Guideline on Similar Biological Medicinal Products)
[4]).
Therefore “biosimilar” does not designate second-entry
versions of biopharmaceuticals whose patent protection has
expired, but rather a high quality product just as in new drug
applications (NDAs). Authorization of biosimilars is granted
on the basis of the strict guidelines of European drug law,2 International Journal of Pediatric Endocrinology
Table 1: Classes of approved recombinant-protein drugs [1].
Class Examples
Hormones
Insulin (e.g., Humulin), glucagon (e.g., Glucagen), human growth hormone (e.g., Humatrope), thyrotropin
(Thyrogen), follicle-stimulating hormone (Gonal-F), lutelnizing hormone (lutropin alfa [Luveris]), human
chorionic gonadotropin (Ovidrel), erythropoietin (e.g., epoctin alfa [Epogen])
Cytokines Interferon alfa (e.g., Roferon-A), granulcyte-colony-stimulating factor (ﬁlgrastim [Neupogen]), interleukin
(e.g., aldesleukin [Proleukin])
Clotting factors Factor VII (NovoSeven), factor VIII (e.g., Kogenate), factor IX (BeneFIX)
Monoclonal antibodies
Antibodies to vascular endothelial growth factor (bevacizumab [Avastin]), epidermal growth factor receptor
(cetuximab [Erbitux]), GPIIb/IIIa receptor (abciximab [ReoPro]), CD20 (rituximab [Rituxan]), and TNF-α
(e.g., inﬂiximab [Remicade])
Vaccine products Hepatitis B surface antigen (e.g., Recomblvax HB), Borrelia burgdorferi outer sourface protein A (LYMErix), +
human papillomavirus major capsid proteins (Gardasil)
Enzymes Glucocerebrosidase (Cerezyme), DNase (Pulmozyme), thrombolytics (e.g., alteplase [Activase]), urate oxidase
(rasburicase, Elitek)
Ovel synthetic proteins Fusion protein of interleukin-2 and diphtheria toxin (denileukin diftitox [Ontak]), soluble TNF receptor linked
to IgG Fc (etanercept [Enbrel])
Novel conjugates
Pegylated proteins: interferon (peginterferon alfa-2a [Pegasys]), granulocyte colony-stimulating factor
(pegﬁlgrastim [Neulasta]), human growth hormone (pegvisomant [Sornavert])
Covalently attached metal chelators: ibrutumomab tiuxetan (Zevalin)
Covalently attached radioactive iodine: Iodine-131 tositumomab (Bexxar)
Covalently attached chemotherapeutics: gemtuzumab ozogarnicin (Mylotarg)
which requires in-depth proof that the second-entry product
is similar to the original product in terms of quality, safety,
and eﬃcacy.
An important prerequisite for the development of
biosimilars or FOPPs has been the advances in analytics
seen over the past two decades. Twenty years ago, available
analytical technologies were not reﬁned enough to allow an
in-depth physicochemical comparison of complex protein
molecules and protein drugs were therefore not amenable
to direct laboratory comparisons. Quality depended on
a consistent controlled and reproducible manufacturing
process.
Today’s analytical techniques enable in-depth investiga-
tion of all the relevant properties of a recombinant protein
orglycoproteinregardingitsprimary,secondary,tertiaryand
quaternarystructures,allowingdirectandthoroughcompar-
ison of the quality and characteristics of biopharmaceuticals
[4].
In the US this process was seriously delayed by several
years after a “Citizen’ s Petition” was ﬁled by both Pﬁzer and
GenentechtodisallowtheapprovalofbiosimilarsbytheFDA
[1].
Sandoz patiently only sought approval for Omnitrope,
a recombinant human growth hormone that is structurally
identical to Pﬁzer’s Genotropin, which itself was approved
under a 1995 new-drug application (NDA). As part of its
application, Sandoz submitted chemical data, bioassays in
hypophysectomized rats, safety studies in rats and rabbits,
human pharmacokinetic and pharmacodynamic (PK/PD)
studiesandresultsofphaseIIIstudies(see,belowfordetails).
After a year of deliberations the FDA decided that it was
unable “to reach a decision on the approvability of the
application because of unresolved scientiﬁc and legal issues”
[5]. Sandoz sued and after protracted legal wrangling from
2003 to 2007 Omnitrope and Valtropin, another FOPPsfrom
Korea manufactured by LG Life Sciences in collaboration
with Biopartners from Switzerland were ﬁnally approved in
2007 after a District Court instructed the FDA to end its
“marathon round of keep-away” [1] and make a decision
about the product [1, 5]. It is true that in 2007 bills were
introduced in the US Congress with the goal of creating
a viable abbreviated approval scheme for FOPPs. Although
there was some well meaning talk that one of the bills would
be included in the recently passed FDA Amendment Act,
unfortunately none reached a ﬂoor vote [1] and the US
approval process continues to lag seriously behind Europe,
which recently also approved biosimilar erythropoetin as
well granulocyte colony stimulating factor (GCSF) (Sandoz,
Press Release 2008).
When the FDA ultimately approved Omnitrope and
Valtropin, it allowed an abbreviated pathway with at least
6-month clinical data from a phase III study. It did so
only because hGH had been historically regulated under
the Federal Food Drug and Cosmetic Act (FFDCA) and
not under Public Health Service Act (PHSA) from 1944
which regulates most protein-based products in the US, for
example, Interferon. Fortunately, a few select recombinant
products such as insulin, glucagons, hGH, and thyrotropin
alpha are governed under the FFDCA from 1938 and are
approved in the US under new-drug applications [1].
In its approval the FDA ﬁnally acknowledged that a
comparison of “end products of diﬀerent manufacturing
processes was possible in select cases because of improve-
ments in the availability of analytical techniques.” Omni-
trope, and implicitly also Valtropin, were approvable because
“it had a well characterized protein structure, a knownInternational Journal of Pediatric Endocrinology 3
Table 2: Comparison of data requirement for generics versus
similar biological medicinal products. BE: bioequivalence; PMS:
postmarketing study.
Classic generics Biosimilars
Manufacturing
Chemical synthesis Genetically modiﬁed cell
lines
Simple microbial
fermentation
Complex fermentation
process
Standard analytics Complex puriﬁcation
process
Formulation
Complex analytical
characterization
Preclinic Generally none
In vitro/in vivo bioassay
Toxicity studies
Local tolerance studies
PK/PD studies
Clinic Generally BE study
Phase I PK/PD
Phase III studies
Phase IIIb studies
Phase IV studes (PMS)
mechanism of action, a lack of glycosylation and a long
and well documented history of clinical use with a safety
and eﬃcacy proﬁle thoroughly described in the literature”
[1]. The FDA should also be able to rely on studies and
analyses done to secure EMEA, Canadian, or Australian
approval.
Even though the EMEA [6–8] and US approval process
requires phase III studies, for example, hGH [9] it did have a
marked eﬀect on lowering costs, contrary to expectations in
the US Senate [10].
Somescientiﬁcissueswhichhaveledwell-meaningcritics
to doubt the clinical utility and safety of FOPPs do remain
unresolved [1]. Most notably the potential for complex
quaternary structure, PD, and immunogenicity,is owing to
changes in manufacturer, inert ingredients and packaging.
For example, in the case of Eprex, a DNA recombinant
erythropoietin, not a biosimilar, serious problems arose
when a stabilizer in the manufacturing process was changed
fromalbumintosorbitolantierythropoietin;antibodieswere
formed and potentially lethal pure red call aplasia developed
as a most serious side eﬀect [13–15]. Thus postmarketing
pharmacovigilance studies will probably be required for all
except the simplest FOPPS for the foreseeable future. These
provisions regarding Phase IV studies are also in place for
Omnitrope in the US and Europe and will also be carried out
for Valtropin once it is being marketed.
In summary two biosimilar somatropins Omnitrope
(Sandoz) and Valtropin (LG Life Sciences, Biopartners) have
recently in 2007 been approved by the US Food and Drug
Administration and previously by EMEA [6–8]a saf o l l o w
on protein product. Omnitrope is being marketed in the US
since 2007 for GHD in children and adults. Valtropin is not
yet on the market, except in Korea.
3. BiosimilarsandFopps for GH inthe US
Biosimilar designates a second entry version of a biophar-
maceutical whose patent protection expired. The term is
considered equivalent to FOPP. It is only reasonable to study
metabolic eﬀects of a FOPP in a very sensitive population,
that is, Growth hormone deﬁciency. Once eﬃcacy is demon-
strated in that model it is extremely unlikely that the drug
willbehavesuddenlydiﬀerentlyinalesssensitivemodel(e.g.,
SGA or Turner Syndrome) [4].
In the FDA ruling neither drug was rated as thera-
peutically equivalent and therefore substitutable for any of
the other approved growth hormone products. That is why
this class of drugs is more appropriately characterized as a
“follow-on protein product.”
There are currently in the US two possible pathways for
approval for follow on protein product, either are found
in section 505 of the Food, Drug and Cosmetic (FDC) Act
applicable to drugs or under section 351 of the PHS Act
applicable to biological products. Omnitrope was approved
under section 505(b) 2 of the FDC Act which is usually
applied to generic drugs and allows for an abbreviated
approval pathway. In the previous years the FDA approved
also other follow-on products under section 505 of the
FDCA. These include GlucaGen (glucagons recombinant for
injection), Hylenex (Hyaluronidase recombinant human),
and Fortical (calcitonin salmon recombinant) Nasal Spray
[1].
4.ClinicalStudieswith
ApprovedBiosimilar GrowthHormones
Following guidelines published ﬁrst by EMEA in 2006 [7–
9] both Valtropin and Omnitrope have chosen the most
sensitive model (prepubertal children with GH deﬁciency)
with stable thyroid hormone and/or glucocorticoid replace-
menttherapiesifindicated,toshowcomparativeeﬃcacyand
safety to the reference biological medicinal product.
Omnitrope contains human GH produced by recombi-
nant technology using E. coli as expression system. During
the clinical development program various formulations of
GH were used, with the active pharmaceutical ingredient, as
follows.
Somatropin Sandoz powder for solution for injection
(Covance).
Somatropin Sandoz powder (Sandoz): formulation to be
marketed as Omnitrope.
Somatropin Sandoz liquid (Sandoz).
The eﬀect of Omnitrope (Covance) was compared in 89
naive children with GHD to Genotropin (Pﬁzer). Eﬃcacy
was similar, the Covance formulation however led to a high
titer of GH antibodies (ABs) (60%) without adverse eﬀects
on growth velocity [11].
These ABs did not aﬀect eﬃcacy or safety of the biosim-
ilar. Their occurrence was most likely related to the presence
of an increased level of host cell protein. After introduction
of additional puriﬁcation steps AB frequency dropped to the
accepted range [16]. In subsequent Omnitrope formulations
no patient developed antibodies against GH and 1 patient4 International Journal of Pediatric Endocrinology
Table 3: Results from omnitrope and valtropin trials [2, 11, 12]. SDS: standard deviation score; PP = per protocol; NS: not signiﬁcant; CI:
conﬁdence interval.
Omnitrope Genotropin 95% CI
Number of Patients 44 45
Duration, months 9 9
Height baseline, cm 113.3 109.3
Height at 9 months, cm 121.9 117.7 −0.59,1.06
Height velocity pretreatment, cm/year 3.8 4.0
Height velocity at 9 months, cm/year 10.7 10.7 −1.35,0.92
Height velocity SDS at baseline, cm/year −2.4 −2.3
Height velocity SDS at 9 months, cm/year 6.1 5.4 −0.81,2.13
Valtropin Humatrope 95% CI
Number of Patients (PP) 98 (70) 49 (32)
Duration, months 12 12
Height baseline, cm 108.4 111.3
Height at 12 months, cm 120.2 122.5 NS
Height velocity pretreatment, cm/year 3.6 3.4
Height velocity at 12 months, cm/year 11.3 10.5 −0.71,0.90
Height velocity SDS at baseline, cm/year −2.19 −2.42
Height velocity SDS at 12 months, cm/year 5.62 5.33 NS
Table 4: Auxological measurements at baseline and after 1 year of treatment with either Valtropin or Humatrope in children with GH
deﬁciency[11,12].Valuesaremean±SDwithmediansinparantheses.HV:heightvelocity;SDS:standarddeviationscore;CA:chronological
age; BA = bone age.
Valtropin N = 70 Humatrope N = 32
HV SDS CA
Pretreatment −2.19 ±1.80 (−1.79) −2.42 ±1.37 (−2.11)
12 months 5.62 ±3.55 (4.86) 5.33 ±3.88 (3.89)
Height SDS CA
Baseline −3.45 ±1.16 (−3.24) −3.17 ±0.80 (−2.93)
12 months −2.26 ±0.91 (−2.15) −2.15 ±0.69 (−2.00)
Height SDS BA
Baseline −0.15 ±1.47 (−0.20) −0.06 ±1.33 (−0.08)
12 months −0.09 ±1.61 (−0.27) −0.00 ±1.40 (0.14)
IGF-I, μg/L
Baseline 47.3 ±37.5( 3 7 .0) 64.1 ±44.6( 5 8 .0)
12 months 158.7 ±104.6 (133.5) 186.6 ±102.5 (170.5)
IGFBP-3, mg/L
Baseline 1.3 ±0.8( 1 .2) 1.6 ±0.9( 1 .3)
12 months 2.4 ±0.7( 2 .5) 2.7 ±0.7( 2 .8)
developed anti-HCP antibodies during the 12 months study
(data on ﬁle with Sandoz).
These studies are still ongoing in the same cohort and a
phase III study is now in its 7th year with centrally measured
IGF-1, carbohydrate metabolism parameters, and antibodies
against GH and host cell protein (HCP) [11].
Valtropin has been produced in S. cerevisiae (yeast cells).
Valtropin was compared to Humatrope in terms of quality,
safety, and eﬃcacy. The registration trial was powered with
98GH deﬁcient children in the Valtropin arm compared to
49 children in the Humatrope arm. This was a 12-months
parallel controlled study. After the initial 12-months period,
all enrolled patients were treated for an additional 12 month
period. Height velocity increases were comparable with both
products (see Table 3)[ 12].
These studies were powered according to strict FDA
guidelinestodetectnoninferiorityata1.8cmgrowthvelocity
diﬀerence.
In addition, one uncontrolled 12 supportive study in
30 treatment-na¨ ıve girls aged 2–9 years with short stature
due to Turner Syndrome was performed [17]. Height
velocity increased signiﬁcantly in this observational study
from baseline values of 3.75 + 1.76cm/year rose to 9.73 +
1.55cm/year.International Journal of Pediatric Endocrinology 5
The Valtropin safety proﬁle was consistent with that
of Humatrope. There were no relevant diﬀerences in the
development of anti-GH AB between Valtropin (2–3%) and
the reference product (3%). Growth was not aﬀected by
AB status. The observed frequency of anti S. cerevisiae AB
(2%) did not raise concern as these AB do not appear to
have adjuvant properties, which could amplify the immune
response (4.16).
PD data (rise in IGF-1 and IGFBP-3) are for both Omni-
trope and Valtropin similarly reassuring when compared to
GenotropinandHumatropeTable 4 [4,11,12](forValtropin
data see Table 4 and [11, 18] for Omnitrope).
5. Areas of Concern
It is unclear at present whether regulatory agencies will
eventually allow commercial use of approved biosimilar
somatropins in non-GH deﬁcient states. In the current
giudelines [6–8, 19] it is considered that the demonstration
of similar eﬃcacy and safety in GH deﬁcient children
can be extrapolated to other indications of the reference
somatropins (Genotropin and Humatrope).
Current guidelines both in Europe and in the US [6–
8,19]proposestudydurationsof6–12monthsforacompar-
ative eﬃcacy and safety assessment in children. None of the
currentlyapprovedbiosimilargrowthhormones“settled”for
this guideline. All carried out studies for signiﬁcantly longer
periods of time (in the case of Omnitrope for 7 years thus far
and in the case of Valtropin for more than 3 years [18, 20]).
A common misconception about biosimilars is that
there is the potential for reduced quality standards. This is
deﬁnitely not the case, as all aspects of the comparability
exercisehavetobefulﬁlledinfullycharacterizingtheproduct
and demonstrating similarity or noninferiority [2].
Both products will be monitored in phase IV phar-
macovigilance programs just like most of the other previ-
ously NDA approved somatropins. These risk-management
programs take into account that long-term information is
necessary for biosimilars as far as carbohydrate metabolism,
AB formation, and the development of IGF-1 receptor
expressing cancers. This approach has been in place for
previously approved growth hormones and it is therefore
reasonable to put a similar program in place for the class
of FOPP or biosimilars medicinal GH products. Given the
low frequency of adverse eﬀe c t si na l lG Hp r o d u c t so n l y
a long-term large pharmacopidemiological study will have
a chance to detect adverse eﬀects. The existing databases
are insuﬃcient to answer the question of tumor-growth
promoting potential of GH eﬀects [21]. Therefore these
potential serious adverse side eﬀects have to be explored
for all growth hormones including biosimilars (B. Weise,
personal comment).
The high AB titers in the initial Omnitrope product
formulation manufactured by Covance are no longer found
in patients receiving the currently marketed formulation. In
fact anti-GH AB and anti-HCP AB titers are not diﬀerent
from the comparator Genotropin. GH is administered in an
unphysiologic fashion, that is, by subcutaneous injection,
there will therefore always be low level AB formation.
Neutralizing or blocking AB titers were never seen with any
biosimilar or FOPP product.
Regarding the issue of switching patients receiving a
growth hormone preparation to a biosimilar medicinal
product, it is of interest that in a recent position paper by
the Arzneimittelkommission (Drug Review Board) of the
German Medical Association [22] voices no concern. The
Board does not see any reason not to switch patients receiv-
ing a biopharmaceutical to a biosimilar medicinal product
if so desired or requested because of lower cost. In other
countries, including the US, third party payers increasingly
demand similar changes as a cost-saving measure.
Ithasbeenargued[23]thatthesafetyofbiosimilarsisnot
“on a par” with the knowledge gained through the previous
a p p r o v a lp r o c e s s e sf o rG H .T h i si sn o tc o r r e c t[ 24]. The
previous growth hormones study data that were submitted
after 12 months data from phase III studies were available
and both EMEA and FDA require 6–12 months data for
submission of biosimilars or FOPPs. Both LGLS/Biopartners
andSandozsubmitted12monthsdata.InthecasesofSandoz
and LGLS/Biopartners now seven- and, respectively, three-
year safety data from phase III studies have been presented
in abstract from[18, 20], providing a degree of scientiﬁc
scrutiny absent from phase IV postmarketing studies. Ideally
the ﬁnal choice of product to be prescribed must be made
by the informed physician [23]. Unfortunately this process
is being dismantled in the US where payors increasingly
prescribe which GH preparations can be used.
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